JNJ vs WVE

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

WAVE Life Sciences continues to represent a high-risk, high-reward opportunity, though its path to 10x growth has become more concentrated following the disappointing WVE-007 obesity data. While the core PRISM platform and rare disease programs (WVE-003 for Huntington's, WVE-006 for AATD) remain promising with prior de-risking, the significant setback in WVE-007 reduces overall pipeline optionalit...